RPRX

Royalty Pharma
D

RPRX

Arincen67/100B
67.290
USD
-0.26
(-0.38%)
Post Trading·68.800USD+1.510(+2.24%)
Last updated: · Delayed 15 min
Fair value63.11Plus+7%48Price 67.2994
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
OverviewFinancialsForecastEarningsDividendsCompany

Royalty Pharma EPS (earnings per share) 2015–2026

Royalty Pharma's diluted EPS in Q3 FY2026, the three months to 30 September 2026, was 0.26 USD, down 61.2% on the same quarter a year before. Royalty Pharma's diluted earnings per share over the last twelve months were 1.33 USD, down 17.9% on the twelve months before. In fiscal year 2025 they were 1.80 USD, down 5.8% on the year before.

Last updated 6 Nov 2026 · Next report 10 Feb 2027

EPS

Growth

Fiscal yearPeriod endingEPSGrowthEPS (basic)
TTM30 Sept 20261.33-17.90%1.69
FY202531 Dec 20251.80-5.76%2.33
FY202431 Dec 20241.91-24.51%1.92
FY202331 Dec 20232.53+2,430.00%3.41
FY202231 Dec 20220.10-93.29%0.10
FY202131 Dec 20211.49+16.41%1.49
FY202031 Dec 20201.28-80.69%1.28
FY201931 Dec 20196.63+70.44%6.63
FY201831 Dec 20183.89+13.74%3.89
FY201731 Dec 20173.42+267.74%3.42
FY201631 Dec 20160.93-3.12%0.93
FY201531 Dec 20150.96—0.96

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Royalty Pharma's EPS

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.